Aquestive Therapeutics (AQST) Total Debt (2017 - 2026)

Aquestive Therapeutics' Total Debt history runs 10 years deep, the most recent figure standing at $58.7 million for Q1 2026.

• On a quarterly basis, Total Debt rose 73.69% year-over-year to $58.7 million in Q1 2026; TTM through Mar 2026 was $58.7 million, a 73.69% increase from a year earlier, with the FY2025 full-year figure at $37.5 million, up 15.33% from the prior year.
• Total Debt advanced to $58.7 million in Q1 2026 per AQST's latest filing, from $37.5 million in the prior quarter.
• Across five years, Total Debt topped out at $58.7 million in Q1 2026 and bottomed at $17.5 million in Q2 2024.
• The 5-year median for Total Debt is $43.6 million (2023), against an average of $42.6 million.
• Across the five-year window, Total Debt slumped 69.48% in 2024 and surged 100.1% in 2025, its largest moves.
• Year by year, Total Debt stood at $52.1 million in 2022, then tumbled by 47.21% to $27.5 million in 2023, then rose by 18.15% to $32.5 million in 2024, then advanced by 15.33% to $37.5 million in 2025, then surged by 56.38% to $58.7 million in 2026.
• Per Business Quant, the three latest AQST Total Debt figures stand at $58.7 million (Q1 2026), $37.5 million (Q4 2025), and $36.3 million (Q3 2025).